Real-World Experience with Pembrolizumab Treatment in Patients with Heavily Treated Recurrent Gynecologic Malignancies
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Purpose: We evaluated the efficacy and safety of pembrolizumab in patients with recurrent gynecologic cancers in real-world practice. Materials and Methods: We conducted a retrospective, single-institution study of patients with recurrent gynecologic malignancies treated with pembrolizumab. The primary endpoints were the objective response rate (ORR) and safety. Results: Thirty-one patients treated with pembrolizumab were included. The primary disease sites were the uterine cervix (n=18), ovaries (n=8), and uterine corpus (n=5). Fifteen of the 31 patients (48%) had an Eastern Cooperative Oncology Group performance status of ≥2. The median number of prior chemotherapy lines was 2 (range, 1–6), and 14 of 31 patients (45%) had received ≥ 3 prior lines of chemotherapy. The overall ORR was 22.6%: specifically, 22.3% (4 of 18 patients), 12.5% (1 of 8 patients), and 40% (2 of 5 patients) for cervical, ovarian, and endometrial cancers, respectively. During a median follow-up of 4.7 months (range, 0.2–35.3), the median time to response was 1.9 months (range, 1.4–5.7). The median duration of response was not reached (range, 8.8-not reached). The median progression-free survival was 2.5 months (95% confidence interval, 1.7-not reached). Adverse events occurred in 20 patients (64.5%), and only 3 (9.7%) were grade ≥3. There was one case of suspicious treatment-related mortality, apart from which most adverse events were manageable. Conclusion: In real-world practice, pembrolizumab was feasible and effective in heavily treated recurrent gynecologic cancer patients with poor performance status who may not be eligible for enrollment in clinical trials.
Abstract
Purpose: We evaluated the efficacy and safety of pembrolizumab in patients with recurrent gynecologic cancers in real-world practice. Materials and Methods: We conducted a retrospective, single-institution study of patients with recurrent gynecologic malignancies treated with pembrolizumab. The primary endpoints were the objective response rate (ORR) and safety. Results: Thirty-one patients treated with pembrolizumab were included. The primary disease sites were the uterine cervix (n=18), ovaries (n=8), and uterine corpus (n=5). Fifteen of the 31 patients (48%) had an Eastern Cooperative Oncology Group performance status of ≥2. The median number of prior chemotherapy lines was 2 (range, 1–6), and 14 of 31 patients (45%) had received ≥ 3 prior lines of chemotherapy. The overall ORR was 22.6%: specifically, 22.3% (4 of 18 patients), 12.5% (1 of 8 patients), and 40% (2 of 5 patients) for cervical, ovarian, and endometrial cancers, respectively. During a median follow-up of 4.7 months (range, 0.2–35.3), the median time to response was 1.9 months (range, 1.4–5.7). The median duration of response was not reached (range, 8.8-not reached). The median progression-free survival was 2.5 months (95% confidence interval, 1.7-not reached). Adverse events occurred in 20 patients (64.5%), and only 3 (9.7%) were grade ≥3. There was one case of suspicious treatment-related mortality, apart from which most adverse events were manageable. Conclusion: In real-world practice, pembrolizumab was feasible and effective in heavily treated recurrent gynecologic cancer patients with poor performance status who may not be eligible for enrollment in clinical trials.
참고문헌 (26)
- Bray F, "Global cancer statistics 2018 : GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries", CA Cancer J Clin, 68, pp.394~424 (2018)
- Naumann RW, "Management strategies for recurrent platinum-resistant ovarian cancer", Drugs, 71, pp.1397~1412 (2011)
- Wright JD, "Contemporary management of endometrial cancer", Lancet, 379, pp.1352~1360 (2012)
- Motzer RJ, "Nivolumab versus everolimus in advanced renalcell carcinoma", N Engl J Med, 373, pp.1803~1803 (2015)
- Robert C, "Pembrolizumab versus ipilimumab in advanced melanoma", N Engl J Med, 372, pp.2521~2532 (2015)
- Herbst RS, "Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer(KEYNOTE-010) : a randomised controlled trial", Lancet, 387, pp.1540~1550 (2016)
- Makker V, "Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer : an interim analysis of a multicentre, open-label, single-arm, phase 2 trial", Lancet Oncol, 20, pp.711~718 (2019)
- Chung HC, "Efficacy and safety of pembrolizumab in previously treated advanced cervical cancer : Results From the Phase II KEYNOTE-158 Study", J Clin Oncol, 37, pp.1470~1478 (2019)
- Tashiro H, "Immunotherapy against cancer-related viruses", Cell Res, 27, pp.59~73 (2017)
- Alemany L, "Time trends of human papillomavirus types in invasive cervical cancer, from 1940 to 2007", Int J Cancer, 135, pp.88~95 (2014)
- Bell D, "Integrated genomic analyses of ovarian carcinoma", Nature, 474, pp.609~615 (2011)
- Dai Y, "Potent immunogenicity in BRCA1-mutated patients with high-grade serous ovarian carcinoma", J Cell Mol Med, 22, pp.3979~3986 (2018)
- Dudley JC, "Microsatellite instability as a biomarker for PD-1 blockade", Clin Cancer Res, 22, pp.813~820 (2016)
- Le DT, "Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade", Science, 357, pp.409~413 (2017)
- Hamanishi J, "Safety and antitumor activity of anti-PD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer", J Clin Oncol, 33, pp.4015~4022 (2015)
- Varga A, "Pembrolizumab in patients with programmed death ligand 1-positive advanced ovarian cancer : analysis of KEYNOTE-028", Gynecol Oncol, 152, pp.243~250 (2019)
- Liu JF, "Assessment of combined nivolumab and bevacizumab in relapsed ovarian cancer : a phase 2 clinical trial", JAMA Oncol, 5, pp.1731~1738 (2019)
- Konstantinopoulos PA, "Single-arm phases 1 and 2 trial of niraparib in combination with pembrolizumab in patients with recurrent platinum-resistant ovarian carcinoma", JAMA Oncol, 5, pp.1141~1149 (2019)
- Marius C. Normann, "Early experiences with PD-1 inhibitor treatment of platinum resistant epithelial ovarian cancer", Journal of Gynecologic Oncology, 30(4), pp.1~10 (2019), 대한부인종양학회[DOI]
- Schwartz LH, "RECIST 1. 1-update and clarification : from the RECIST committee", Eur J Cancer, 62, pp.132~137 (2016)
- Frenel JS, "Safety and efficacy of pembrolizumab in advanced, programmed death ligand 1-positive cervical cancer : Results From the Phase Ib KEYNOTE-028 Trial", J Clin Oncol, 35, pp.4035~4041 (2017)
- Naumann RW, "Safety and efficacy of nivolumab monotherapy in recurrent or metastatic cervical, vaginal, or vulvar carcinoma : Results From the Phase I", II CheckMate 358 Trial, 2019, pp.37, 2825~2834
- Santin AD, "Phase II evaluation of nivolumab in the treatment of persistent or recurrent cervical cancer(NCT02257528", NRG-GY002), 2020, pp.157, 161~166
- Marabelle A, "Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability", mismatch repair-deficient cancer : Results From the Phase II KEYNOTE-158 Study, 2020, pp.38, 1~10
- Disis ML, "Efficacy and safety of avelumab for patients with recurrent or refractory ovarian cancer : Phase 1b Results From the JAVELIN Solid Tumor Trial", JAMA Oncol, 5, pp.393~401 (2019)
- Ott PA, "Safety and antitumor activity of pembrolizumab in advanced programmed death ligand 1-positive endometrial cancer : Results From the KEYNOTE-028 Study", J Clin Oncol, 35, pp.2535~2541 (2017)